Evidence map›Paper›PMID 35493026›Full record

ArticleRSC advances2020

An improved synthesis of telmisartan

Junchi Zhang, Rui Li, Fuqiang Zhu, Changliang Sun, Jingshan Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Rational Design and Synthesis of AT1R Antagonists.Molecules (Basel, Switzerland) · 2021
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junchi ZhangCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS) 555 Zuchongzhi Road Shanghai 201203 People's Republic of China shenjingshan@simm.ac.cn.
Rui LiCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS) 555 Zuchongzhi Road Shanghai 201203 People's Republic of China shenjingshan@simm.ac.cn.
Fuqiang ZhuTopharman Shanghai Co., Ltd Building 1, No. 388 Jialilue Road, Zhangjiang Hitech Park Shanghai 201203 People's Republic of China changliang.sun@topharman.cn.
Changliang SunTopharman Shanghai Co., Ltd Building 1, No. 388 Jialilue Road, Zhangjiang Hitech Park Shanghai 201203 People's Republic of China changliang.sun@topharman.cn.
Jingshan ShenCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS) 555 Zuchongzhi Road Shanghai 201203 People's Republic of China shenjingshan@simm.ac.cn.ORCID https://orcid.org/0000-0001-9679-9934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A concise synthetic route was designed for making telmisartan. The key bis-benzimidazole structure was constructed

Identifiers

PMID35493026
PMCPMC9051534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.